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Abstract--Sphingosine kinase (there are two isoforms, SK1 and SK2) catalyses the formation 
of sphingosine 1-phosphate (S1P), a bioactive lipid that can be released from cells to activate 
a family of G protein-coupled receptors, termed S1P1-5. In addition, S1P can bind to 
intracellular target proteins, such as HDAC1/2, to induce cell responses.  There is increasing 
evidence of a role for S1P receptors (e.g. S1P4) and SK1 in cancer, where high expression of 
these proteins in ER negative breast cancer patient tumours is linked with poor prognosis.  
Indeed, evidence will be presented here to demonstrate that S1P4 is functionally linked with 
SK1 and the oncogene HER2 (ErbB2) to regulate mitogen-activated protein kinase pathways 
and growth of breast cancer cells.  Although much emphasis is placed on SK1 in terms of 
involvement in oncogenesis, evidence will also be presented for a role of SK2 in both T-cell 
and B-cell acute lymphoblastic leukemia.  In patient T-ALL lymphoblasts and T-ALL cell 
lines,  we have demonstrated that SK2 inhibitors promote T-ALL cell death via autophagy 
and induce suppression of c-myc and PI3K/AKT pathways.  We will also present evidence 
demonstrating that certain SK inhibitors promote oxidative stress and protein turnover via 
proteasomal degradative pathways linked with induction of p53- and p21-induced growth 
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arrest.  In addition, the SK1 inhibitor, PF-543 exacerbates disease progression in an 
experimental autoimmune encephalomyelitis mouse model indicating that SK1 functions in 
an anti-inflammatory manner.  Indeed, sphingosine, which accumulates upon inhibition of 
SK1 activity, and sphingosine-like compounds promote activation of the inflammasome, 
which is linked with multiple sclerosis, to stimulate formation of the pro-inflammatory 
mediator, IL-1β.  Such sphingosine like compounds could be exploited to produce 
antagonists that diminish exaggerated inflammation in disease.   The therapeutic potential of 
modifying the SK-S1P receptor pathway in cancer and inflammation will therefore, be 
reviewed. 
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Introduction--Formation of the bioactive lipid, sphingosine 1-phosphate (S1P) is catalysed by 
sphingosine kinase.  There are two isoforms of sphingosine kinase (SK1 and SK2) which 
differ in their subcellular localisations, regulation and functions (Pyne et al., 2009). The S1P 
formed by these enzymes can either be exported from cells (through transporter proteins e.g. 
Spns2) and act as a ligand on a family of five S1P-specific G protein coupled receptors (S1P1-
5) (Blaho and Hla, 2014) or can bind to specific intracellular target proteins. For instance S1P 
formed by nuclear SK2 inhibits HDAC1/2 activity to induce c-fos and p21 expression (Hait et 
al., 2009). Dephosphorylation of S1P is catalysed by S1P phosphatase and the sphingosine 
formed is then acylated to ceramide catalysed by ceramide synthase isoforms (Stiban et al., 
2010). S1P can also be irreversibly cleaved by S1P lyase to produce (E)-2 hexadecenal and 
phosphoethanolamine (Degagné et al., 2014).  The interconversion of ceramide to 
sphingosine and S1P has been termed the sphingolipid rheostat (Newton et al., 2015).  In this 
model, shifting the balance toward ceramide induces apoptosis, while predominance of S1P 
formation promotes cell survival.   For instance, ceramide activates protein phosphatase 2A 
(Dobrowsky et al., 1993), which dephosphorylates phosphorylated AKT (Zhou et al., 1998) 
and thereby alters BAD/Bcl2 regulation to induce apoptosis (Zundel and Giaccia, 1998).  In 
contrast, S1P promotes cell survival, involving for instance, activation of the extracellular 
signal regulated kinase-1/2  (ERK-1/2) pathway (Pyne et al., 2009).  However, the 
sphingolipid rheostat exhibits greater complexity, as certain ceramide species regulate 
processes other than apoptosis, such as autophagy and proliferation.  This suggests temporal 
and spatial regulation, where the functionality of the sphingolipid rheostat is governed by 
compartmentalised signalling involving, for instance, ceramide synthase isoforms that 
produce different ceramide species with specific stress-dependent signalling functions that 
govern a defined cellular outcome e.g. apoptosis versus proliferation.  The conversion of S1P 
to (E)-2 hexadecenal and phosphoethanolamine is also considered an exit point in the 
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sphingolipid metabolic pathway, but (E)-2 hexadecenal has potential signalling functions 
(Kumar et al., 2011) and both (E)-2 hexadecenal and phosphoethanolamine can be further 
metabolised to produce phospholipids that have additional defined signalling functions in 
cells (Nakahara et al., 2012).  Therefore, the regulation of the sphingolipid rheostat in 
different cellular compartments is likely to impact significantly on lipid signalling pathways 
that regulate cell context specific physiology and pathophysiology. 
 
S1P receptors, sphingosine kinase and cancer--S1P has been implicated in regulating cellular 
processes, some of which underlie the hallmarks of cancer.  First, over-expression of SK1 
promotes the Ras dependent transformation of fibroblasts into fibrosarcoma (Xia et al., 
2000).  Second, S1P promotes neovascularisation of tumours (LaMontagne et al., 2006).  
Third, S1P promotes inflammatory responses involved in cancer progression.  Thus, S1P 
enhances colitis associated cancer via an amplification loop involving SK1, S1P1, NFκB, 
STAT3 and IL-6 (Liang et al., 2013; Pyne and Pyne, 2013).   Fourth, SK1 maintains the 
survival of cancer cells (a process termed ‘non-oncogenic’ addiction (Vadas et al., 2008)), 
promotes acquisition of replicative immortality and drives hormone-independent growth in 
prostate and breast cancer (for review see Pyne and Pyne, 2010).  Fifth, S1P binding to 
S1P1/S1P3 promotes growth and enhances migration of cancer cells (for review see Pyne and 
Pyne, 2010) and SK1 regulates microenvironmental interaction between cancer cells and 
tumour associated myofibroblasts to promote metastasis (Albinet et al., 2014; Pyne and Pyne, 
2014).  Sixth, inhibition/down-regulation of SK1 blocks the Warburg effect to which cancer 
cells are addicted for ATP production and anabolic metabolism (Watson et al., 2013). 
  
From a clinical perspective, we have established that high tumour expression of SK1 is 
associated with reduced survival and increased disease recurrance rates in estrogen receptor 
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(ER)-positive  breast cancer patients (Watson et al., 2010; Long et al., 2010a; Ohotski et al., 
2013).  In addition, larger, more vascularised treatment resistant tumours are formed when 
cancer cells over-expressing SK1 are injected or implanted into mice (for review see Pyne 
and Pyne, 2010).  There is also a substantial body of evidence to demonstrate a role for S1P 
receptors in cancer cell migration (for review see Pyne and Pyne, 2010). Moreover, we 
established that high S1P1 and S1P3 expression in tumours of ER positive breast cancer 
patients are associated with poor prognosis (Watson et al., 2010).  We have also used a breast 
cancer cell line (MCF-7 cells) to demonstrate that S1P binding to S1P3 stimulates the 
accumulation of phosphorylated ERK-1/2 into membrane ruffles/lamellipodia and the 
nucleus to promote migration of MCF-7 breast cancer cells (Long et al., 2010a). Moreover, 
S1P binding to S1P3 promotes the re-localisation of SK1 from the cytoplasm to membrane 
ruffles/lamellipodia of MCF-7 cells (Long et al., 2010a), thereby demonstrating functional 
regulation of SK1 by S1P/S1P3.  In addition, siRNA knockdown of SK1 reduces S1P3 
expression and ERK-1/2 activation in response to S1P, indicating that SK1 and S1P3 function 
in an amplification loop to promote ER positive breast cancer progression (Long et al., 
2010a).  Therefore, SK1 regulates the expression level of S1P3, and this enables ER positive 
breast cancer cells to potentially match S1P released into the microenvironment with the 
required effector response. 
 
We also reported that high tumour expression of S1P4 and SK1 are associated with shortened 
disease-specific survival and disease recurrence times in patients with ER negative breast 
cancer (Ohotski et al., 2012).  Stratification of the patient cohort to include only ER, PgR, 
HER2 negative tumours established a detrimental effect of tumour S1P4 receptor expression 
on disease-specific survival (Pyne et al., 2012).  Therefore, S1P4 is an important biomarker 
for poor prognosis in ER negative breast cancer patients (Pyne et al., 2012).  Furthermore, 
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SK1 and S1P4 are functionally linked in ER negative MDA-MB-453 cells as S1P stimulation 
of the ERK-1/2 pathway mediated by S1P4 is blocked by SK1 inhibitors (Ohotski et al., 
2012).  We have also demonstrated that oncogenic HER2/ErbB2 functionally interacts with 
S1P4 in ER negative MDA-MB-453 breast cancer cells (Long et al., 2010b).  Thus, S1P 
binding to S1P4 in these cells stimulates activation of ERK-1/2 and this is contingent on 
HER2 and is independent of EGF receptor transactivation.  Therefore, siRNA knockdown of 
HER2 or S1P4, but not EGF receptor or S1P2 receptor ablated  S1P-stimulated ERK-1/2 
activation and this was recapitulated using the ErbB2 inhibitor II, but not the EGF receptor 
tyrosine kinase inhibitor, AG1478 (Long et al., 2010b).  Moreover, treatment of MDA-MB-
453 breast cancer cells with S1P stimulated the tyrosine phosphorylation of HER2 and this 
was blocked by the S1P2/4 antagonist, JTE-013 (Long et al., 2010b).  Therefore, the S1P4-
HER2 signalling platform enhances signalling gain in response to S1P (Figure 1); this is 
significant as ERK-1/2 is implicated in promoting metastasis.  Indeed, high S1P4 expression 
in tumours of ER negative breast cancer patients is also correlated with node positive status, 
suggesting a role for S1P4 in metastasis (Ohotoski et al., 2012; Pyne et al., 2012).  The link 
between S1P and metastasis is further evidenced by studies from Ponnusamy et al. (2012), 
who demonstrated a reduction in systemic S1P inhibits TRAMP-induced prostate cancer 
growth in TRAMP+/+Sk1-/- mice or lung metastasis of various cancer cells in Sk1-/- mice.  
SK1 loss promotes the expression of breast carcinoma metastasis suppressor 1 (Brms1).  
Furthermore, S1P binding to S1P2 reduces Brms1 expression in these cancer cells.    The 
finding that host S1P can increase dissemination of breast cancer cells suggests complex 
interplay between these cancer cells and the microenvironment.  This is supported by the 
studies of Albinet et al. (2014), who demonstrated an important role of melanoma SK1 in 
promoting the differentiation of fibroblasts into myofibroblasts.  The myofibroblast SK1 then 
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stimulates S1P-dependent metastasis of melanoma cells by providing S1P that is released and 
binds to the S1P3 receptor on melanoma cancer cells (Albinet et al., 2014).   
 
We have also identified a functional link between S1P4 and S1P2 receptors in ER negative 
breast cancer cells.  Thus, pre-treatment of HA-S1P2 over-expressing MDA-MB-231 cells 
with the S1P4 antagonist CYM50367 or SK2 inhibitors or with S1P4 or SK2 siRNA promotes 
the nuclear accumulation of HA-tagged S1P2 and this is associated with growth arrest 
(Ohotski et al., 2014).  These findings identify for the first time a signalling pathway in which 
S1P4 functions to prevent nuclear translocation of S1P2 to promote the growth of ER negative 
breast cancer cells.  We proposed that heterodimerisation of S1P2 and S1P4 at the plasma 
membrane in response to S1P might provide a molecular trap that prevents translocation of 
S1P2 to the nucleus.  This suggests that plasma membrane and nuclear S1P2 might elicit 
opposite effects on cancer progression.  Thus, plasma membrane S1P2 might function in 
concert with S1P4 to promote cancer progression, while nuclear S1P2 is associated with 
growth arrest.  Tyrosine phosphorylated Src (Y416) also translocates to the nucleus of MDA-
MB-231 cells treated with SK2 inhibitors or SK2 siRNA, but not S1P4 siRNA (Ohotski et al., 
2014). 
 
SK2 and T-ALL--Acute lymphoblastic leukaemia is the most common type of paediatric 
cancer, affecting approximately one in every 2,000 children, mostly at between 2 and 5 years 
of age.  Despite aggressive treatment approaches, including transplantation and new salvage 
regimens, most children with relapsed T-cell acute lymphoblastic leukaemia (T-ALL) will 
not be cured.  In contrast, the clinical prognosis for adults with T-ALL, which is more 
common, is very poor indeed, with cure rates of, at best, 40%. T-ALL represents a malignant 
disorder arising from the neoplastic transformation of T-cell progenitors.  Treatment options 
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include radiation therapy and prednisolone or dexamethasone, vincristine, asparaginase 
(paediatric patients) and daunorubicin (used in adult ALL).  The development of chemo-
resistance to these established therapeutic agents is a significant problem for effective 
treatment of this cancer.  Current novel approaches for treatment of T-ALL include targeting 
phosphatidylinositol 3-kinase (PI3K)/mTOR and Notch1 signalling (gamma-secretase 
inhibitors).  However, PI3K/mTOR inhibitors increase Notch-c-Myc activity and this can 
result in chemo-resistance in T-ALL (Shepherd et al. 2013).  In addition, one major side 
effect of first-line Notch inhibitors is gastrointestinal toxicity and diarrhoea (Garber, 2007). 
Notch inhibitors might also promote certain cancers as Notch is a tumor suppressor (Nicolas 
et al. 2003).  Therefore, there is a significant unmet medical need in the treatment of T-ALL 
and new and more effective therapeutic strategies displaying less toxicity and lack of chemo-
resistance are required.   
 
We have synthesised two structurally distinct, moderately potent, SK2-selective inhibitors 
((R)-FTY720 methylether (ROMe), Ki =16 µM (Lim et al., 2011a) and F-02 ((2S, 3R) 
sphinganine derivative), Ki = 22 µM (Byun et al., 2013). ROMe induces the autophagic death 
of T-ALL cell lines and patient lymphoblasts (EC50 = 10 µM; (Evangelisti et al., 2014)) and 
no resistant sub-population of cells survive. Similarly, F-02 kills the entire population of T-
ALL cells.  Significantly, treatment of T-ALL cells with ROMe also reduces phosphorylated 
AKT (S473) and c-Myc levels, which are prognostic markers for T-ALL disease progression. 
Moreover, SK2 inhibitor genetic signatures are correlated to a publicly available gene 
expression dataset derived from paediatric T- and B-ALL patients (Wallington-Beddoe et al., 
2014).  In addition, SK2 has been implicated in maintaining cancer cell survival in various 
tumours. Thus, siRNA knockdown of SK2 expression has been shown to induce autophagic 
death of several different cancer cell lines (Gao & Smith, 2011) and S1P, formed by SK2, can 
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inhibit HDAC1/2 to induce epigenetic regulation of genes involved in B-ALL, such as c-Myc 
(Hait et al., 2009; Wallington-Beddoe et al., 2014). Significantly, the death of T-ALL cells 
induced by ROMe is reversed by inhibitors of autophagy but not apoptosis (Evangelisti et al., 
2014).  In addition, preliminary studies demonstrate that shRNA knockdown of SK2 in T-
ALL cells induces autophagy and reduces colony formation (unpublished data, Evangelisti, 
Martelli, Pyne and Pyne).  The key issue here is that the moderately potent SK2 inhibitor, 
ROMe kills the entire population of T-ALL cells (i.e. no sub-population survives).  This 
contrasts with the effect of a moderately potent inhibitor of both SK1 and SK2 activity.  For 
example, SKi (2-(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole)) kills only ~70% of the T-
ALL cell population.  A residual sub-population survives because of an endoplasmic 
reticulum stress response that is induced by SK1 inhibition. This effect appears to over-ride 
the concurrent inhibition of SK2 activity, thereby preventing autophagic death. Consistent 
with this, the highly selective inhibitor of SK1, PF-543, Ki = 14 nM (Byun et al., 2013) fails 
to kill T-ALL cells.  These findings provide a strong rationale for the development of highly 
selective SK2 inhibitors for treatment of B-ALL and T-ALL. 
 
To date, we have used X-ray crystallography and structural activity relationship/homology 
modelling to deduce the requirements for producing highly potent and selective SK1 and SK2 
inhibitors.  In this regard, we are the first group to successfully crystallize SK1 bound with 
PF-543 in the sphingosine binding site at 1.8 Å resolution (Wang et al., 2014).  Using our 
existing homology model and the crystal structure of PF-543-bound SK1, we have identified 
the key structural requirements to promote inhibitor selectivity for SK2 over SK1. Our 
models suggest that the region that accommodates the head group of the SK2 selective 
inhibitor, ROMe, appears more restricted in SK1 than SK2 due to two key amino acid 
differences (V304/L517 in SK2 corresponding to I260/M358 in SK1b, which contains an 86 
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amino-acid N-terminal extension on SK1a). Compounds such as ROMe with 3D-steric 
demand in this region impart selectivity for SK2 over SK1.   
 
Ubiquitin-proteasomal degradation of SK1--We have synthesised and characterised a number 
of structurally similar SK1 selective orthosteric inhibitors, including RB-005 (1-(4-
octylphenethyl)piperidin-4-ol) (Baek et al., 2013) and 55-21 (1-deoxysphinganine analogue) 
(Byun et al., 2013) and allosteric SK1 inhibitors, such as (S)-FTY7200 vinylphosphonate 
(Lim et al., 2011b).  A common feature of these inhibitors is that they induce the ubiquitin-
proteasomal degradation of SK1 in solid cancer cell lines (Loveridge et al., 2010; Tonelli et 
al., 2010; Lim et al., 2011b) and proliferating vascular smooth muscle cells (Loveridge et al., 
2010; Baek et al., 2013; Byun et al., 2013). This leads to inhibition of DNA synthesis (Byun 
et al., 2013) and is recapitulated by siRNA knockdown of SK1 expression.   
 
The ubiquitin-proteasomal degradation of SK1 is correlated with either binding and/or 
inhibition of SK1 catalytic activity.  Thus, PF-543, which exhibits a Ki of 14nM for SK1 
induces proteasomal degradation of SK1 at nM concentrations in solid cancer cells (Byun et 
al., 2013).  Therefore, the ubiquitin-proteasomal degradation of SK1 appears to be 
conformationally directed by inhibitor binding.  Nevertheless, PF-543 lacks cytotoxic effects 
in 1483 head and neck cancer cells (Schnute et al., 2012).  However, the complexity of the 
sphingolipid rheostat is not well understood, and PF-543 might inhibit other sphingolipid 
enzymes that neutralise the effect of inhibiting/down-regulating SK1 activity.  For instance, 
the accumulation of ceramide is essential for induction of apoptosis, and PF-543 fails to 
modulate ceramide levels in 1483 head and neck cancer cells (Schnute et al., 2012).  Indeed, 
we have shown that the SK1 selective inhibitor RB-005 also inhibits CerS5 activity, which 
would prevent ceramide formation (unpublished data, Pyne, Pyne and Futerman).   
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However, other very poor inhibitors of SK1 and SK2 such as SKi (2-(p-hydroxyanilino)-4-(p-
chlorophenyl) thiazole)) also induce the proteasomal degradation of SK1 via a mechanism 
that is only partially dependent on direct binding to SK1 (Loveridge et al., 2010). We have 
demonstrated that SKi induces the proteasomal degradation of SK1a and SK1b (which has an 
86 amino-acid N-terminal extension compared to SK1a) in androgen-sensitive LNCaP 
prostate cancer cells and this results in a reduction in S1P levels and an increase in 
sphingosine and C22:0 and C24:0 ceramide levels and the induction of apoptosis (Loveridge 
et al., 2010).   SKi also induces proteasomal degradation of SK1a in androgen-independent 
LNCaP-AI cells, but fails to reduce SK1b levels (Loveridge et al., 2010), which is possibly a 
consequence of a compensatory increase in SK1b mRNA expression in these cells.  This is 
associated with a failure to increase C22:0 and C24:0 ceramide levels and the absence of 
apoptosis (Loveridge et al., 2010; Lim et al., 2012).  Sensitivity to apoptosis can be restored 
to these cells by either using the allosteric inhibitor, (S)-FTY720 vinylphosphonate (Tonelli 
et al., 2010) or by combined treatment with SK1 siRNA (to prevent mRNA translation of 
SK1a and significantly, SK1b) and SKi (Loveridge et al., 2010).  Further, evidence 
supporting the concept that modulation of the sphingolipid rheostat can result in apoptosis, is 
provided by the finding that the siRNA knockdown of SK1 in MCF-7 cells induces 
accumulation of ceramide and promotes apoptosis of these cells (Taha et al., 2006) and this 
can be recapitulated with SK1 inhibitors, which induce proteasomal degradation of SK1 
(Tonelli et al., 2010).   
 
Treatment of androgen sensitive LNCaP prostate cancer cells with SKi also induces the 
proteasomal degradation of several proto-oncogenes with short stability half-lives (e.g. c-
Myc, Cyclin D1) leading to catastrophic collapse of signalling networks that normally 
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function to inhibit apoptosis of these cells (Loveridge et al., 2010).  This is associated with a 
substantial increase in the levels of several different molecular species of dihydroceramide 
(Loveridge et al., 2010) and we therefore, proposed that SKi might inhibit dihydroceramide 
desaturase.  Dihydroceramide desaturase is the enzyme that catalyses the formation of 
ceramide from dihydroceramide.  The inhibition of dihydroceramide desaturase by SKi 
(Cingolani et al., 2014) would therefore lead to the accumulation of dihydroceramide and this 
appears to induce activation of the proteasome.  Consistent with this, the dihydroceramide 
desaturase inhibitor, fenretinide also promotes the degradation of SK1a in androgen-
independent LNCaP-AI prostate cancer cells (unpublished data, McNaughton, Pyne and 
Pyne).  Dihydroceramide levels also increase in response to SKi in androgen-independent 
LNCaP-AI prostate cancer cells. 
 
ABC294640 is an SK2 specific inhibitor (Ki = 10 µM, (French et al. 2010)) with no 
inhibition of SK1 activity up to 100 µM.  ABC294640 is currently in clinical trials for 
treatment of solid tumours and refractory/relapsed diffuse large B-cell lymphoma.  
Interestingly, ABC294640 induces the proteasomal degradation of c-Myc in multiple 
myeloma cancer cells (Venkata et al., 2014), an effect that is reminiscent of that induced by 
SKi in prostate cancer cells (Loveridge et al., 2010; Watson et al., 2013).   Indeed, we have 
found that ABC294640 induces the proteasomal degradation of SK1a in both androgen-
independent LNCaP-AI prostate cancer cells and HEK 293T cells (unpublished data, 
McNaughton, Pyne and Pyne).  Therefore, ABC294640 cannot be defined as a SK2 specific 
inhibitor as it removes SK1a from cancer cells via an indirect mechanism.   
 
The treatment of androgen-independent LNCaP-AI prostate cancer cells with SKi or 
ABC294640 or fenretinide induces the expression of p53 and p21 (unpublished data, 
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McNaughton, Pyne and Pyne; Watson et al., 2013).  In contrast, SK1 selective (PF-543) or 
SK2 selective (ROMe) inhibitors or siRNA knockdown of SK1 or SK2 fail to induce p53/p21 
expression (unpublished data, McNaughton, Pyne and Pyne).  These findings suggest that the 
effect of SKi and ABC294640 on p52/p21 expression are likely mediated by 
dihydroceramide desaturase inhibition as this is recapitulated by fenretidine.  The increase in 
dihydroceramide levels combined with the proteasomal degradation of SK1a and possibly 
inhibition of SK2 activity promotes growth arrest associated with an increase in the 
expression of markers of senescence in androgen-independent LNCaP-AI cells.  Although, 
SKi increases dihydroceramide levels in androgen-sensitive LNCaP cells, p53 expression is 
not elevated in these cells suggesting the absence of a key regulatory step involved in 
controlling p53 in this cell line. 
 
In summary, the SKi-induced proteasomal degradation of SK1a and SK1b is linked with 
apoptosis of androgen-sensitive LNCaP prostate cancer cells. SK2-selective inhibitors do not 
induce the apoptosis of androgen-sensitive LNCaP prostate cancer cells.  In contrast, 
androgen-independent LNCaP-AI cells are resistant to apoptosis in response to SKi and 
instead undergo a p53/p21-dependent growth arrest that appears to be a consequence of an 
inhibitory action on dihydroceramide synthase, SK1a and possibly SK2.  This pathway is 
summarised in Figure 2. 
 
Sphingosine kinase 1, Sphingosine and the inflammasome--Multiple sclerosis is an 
autoimmune inflammatory demyelinating disease that involves destructive effects of reactive 
T-lymphocytes.  A prognostic relationship exists between IL-1β levels, disease progression 
and mutation of the NOD-like receptor family, pyrin domain containing 3 (Nlrp3) gene, and 
which is associated with multiple sclerosis-like lesions (Compeyrot-Lacassagne et al., 2009; 
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Dodé, et al., 2002).   This is supported by evidence showing that NLRP3 (Nlrp3-/-) mice 
develop mild symptoms in an experimental autoimmune encephalomyelitis (EAE) model and 
this is associated with reduced numbers of IFNγ- and IL-17-expressing TH cells in peripheral 
lymphoid tissues and the spinal cord (Gris et al., 2010; Inoue et al., 2012). Microglial cells 
are activated by IL-1β and these cells stimulate T-lymphocytes with self-antigen during the 
development of EAE.  Furthermore, IL-1 receptor deficient mice develop mild EAE (Sutton 
et al., 2006).  There is also a link between the NLRP3 and the sphingosine mimetic, FTY720, 
which has been shown to activate PP2A and to stimulate IL-β release from macrophages 
(Luheshi et al., 2012).  FTY720 modulates the immune response by preventing egress of T-
lymphocytes from lymph nodes (Hla and Brinkmann, 2011).  FTY720 (GilenyaTM) is 
licenced for oral treatment of relapsing multiple sclerosis and is a prodrug, which is 
phosphorylated by SK2.  FTY720 phosphate is a functional antagonist of S1P1, causing its 
proteasomal degradation and removal from T-lymphocytes (Hla and Brinkmann, 2011).  
Since T-lymphocytes use an S1P gradient to egress from lymph nodes, FTY720 is able to 
prevent this by creating S1P1 null T-lymphocytes that do not respond to the S1P gradient.  
This halts egress of T-lymphocytes from lymph nodes, thereby ablating their action on the 
CNS in multiple sclerosis.   
 
We have demonstrated that administration of the SK1 inhibitor, PF-543 (0.4 mg/kg) to mice 
increases disease progression in the EAE model of muliple sclerosis and this was associated 
with a considerable increase in the infiltration of CD4+ T-cells, CD11b+ monocytes and 
F4/80+ macrophages in the spinal cord (Figure 3).  EAE is also associated with increased 
SK1 expresssion in the spinal cord, possibly due to the influx of inflammatory cells 
expressing this enzyme (Figure 3).  These findings indicate that SK1 functions in an anti-
inflammatory manner in EAE.  During sterile inflammation, danger-associated molecular 
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patterns (DAMPs) are liberated from dead cells to promote the innate immune responses. The 
NLRP inflammasome senses DAMPs leading to recruitment of the apoptosis-associated 
speck-like protein containing a caspase recruitment domain (ASC).  Caspase 1, which cleaves 
pro-IL-1β to produce bioactive IL-1β, is then recruited to the inflammasome and activated 
(Brough and Rothwell, 2007). DAMPs might also be released from damaged lysosomal 
membranes, which is regulated by lysosomal proteases, such as cathepsin B (Hornung and 
Latz, 2010). Recently, Luheshi et al., (2012) demonstrated that sphingosine stimulates 
NLRP3-dependent release of IL-1β from LPS-stimulated macrophages.  This involves the 
sphingosine-dependent activation of protein phosphatase 2A and/or protein phosphatase 1 
(PP2A/PP1). We have assessed the effect of sphingosine on IL-1β release from macrophages, 
primarily as the removal of sphingosine by SK1 could account for its anti-inflammatory 
function in EAE.  Treatment of differentiated U937 macrophage-like cells with sphingosine 
alone or in the presence of LPS, enhanced IL-1β release (Boomkamp et al., 2015). The 
increase in LPS-stimulated IL-1β release by sphingosine was reduced by pretreatment of cells 
with the caspase-1 inhibitor, Ac-YVAD-CHO, consistent with a model in which sphingosine 
stimulates the inflammasome (Boomkamp et al., 2015).  However, this enhancement was also 
reduced by pretreatment of cells with the cathepsin B inhibitor, CA074Me, but not by the 
PP2A inhibitor, okadaic acid, indicating a predominant role for lysosomal destabilization in 
mediating the effect of sphingosine in differentiated U937 macrophage like cells (Boomkamp 
et al., 2015). Therefore, the anti-inflammatory function of SK1 in EAE might be partly 
related to its ability to reduce the bioavailability of sphingosine, thereby ablating its DAMP 
activity in modulating the innate immune response.   
 
We have also assessed the effect of ether glycerol lipid, 77-6 ((2S, 3R)-4-(Tetradecyloxy)-2-
amino-1,3-butanediol) which is chemically similar to sphingosine and is a substrate for 
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sphingosine kinases, on IL-1β release from macrophages.  Treatment of differentiated U937 
macrophage-like cells with 77-6 enhanced IL-1β release; either alone or in the presence of 
LPS.  However, in contrast with sphingosine the effect of 77-6 on IL-1β release is not 
affected by cathepsin B inhibitor, but is diminished by the caspase-1 inhibitor, Ac-YVAD-
CHO (Boomkamp et al., 2015).   One could also argue that enhancing inflammasome activity 
with such sphingosine mimetics might represent a useful strategy for boosting innate 
immunity against invading pathogens. An additional strategy would be to identify allosteric 
activators of SK1 to increase S1P levels in vivo to promote an anti-inflammatory effect, 
which is independent of the S1P gradient.  This is based on the finding that T-cell 
redistribution in lymphoid organs is unaffected in SK1 knockout mice (Allende et al., 2004). 
Alternative approaches to develop new therapeutics in the multiple sclerosis area focus on 
S1P receptor modulators and S1P lyase inhibitors.  S1P lyase catalyses the degradation of 
S1P (Cosconati and Novellino, 2014) and inhibitors are therefore intended to raise lymphoid 
compartment S1P levels in vivo in order to eliminate the S1P gradient, thereby preventing T-
cell egress.     
 
Conclusion--The therapeutic potential of targeting the S1P signalling pathway in cancer and 
inflammation provides significant promise.  This extends to targeting S1P receptor systems 
and the enzymes involved in promoting formation/degradation of S1P.  Compounds can be 
designed to force ‘mild’ or ‘severe’ phenotypes based on whether they conformationally 
induce proteasomal degradation of SK1 or cause activation of the proteasome to instigate 
catastrophic collapse of cancer signalling networks.  In terms of multiple sclerosis, the basis 
of intervention might be to produce activators of sphingosine kinase and/or sphingosine 
antagonists that prevent functioning of the inflammasome.   
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ABBREVIATIONS 
ASC, Apoptosis-associated speck-like protein containing a caspase recruitment domain; 
DAMPs, Danger associated molecular patterns; EAE, experimental autoimmune 
encephalomyelitis; HER2, Human epidermal growth factor related receptor 2; ERK, 
extracellular signal regulated kinase; mTOR, mammalian target of rapamycin; LPS, 
lipopolysaccharide; NLRP3, NOD-like receptor family, pyrin domain containing 3; IFNγ, 
interferon gamma; IL-1β, interleukin-1beta; PI3K. Phosphoinositide 3-kinase; PP2A, protein 
phosphatase 2A; PP1, protein phosphatase 1; SK, sphingosine kinase; S1P, sphingosine 1-
phosphate; S1P1, sphingosine 1-phosphate receptor-1; TH, T helper cells. 
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Figure 1  The functional interaction between S1P4 and HER2 in estrogen receptor 
negative breast cancer cells. S1P binding to the S1P4 receptor induces the tyrosine 
phosphorylation of HER2 and the functional interaction between HER2 and S1P4 increases 
signalling gain in terms of the S1P-induced stimulation of the ERK-1/2 pathway that might 
be linked to metastasis.  In contrast with other studies which demonstrate that the EGF 
receptor is a preferred partner of HER2, there is no functional interaction between EGF 
receptor, HER2 and S1P4 in estrogen receptor negative MDA-MB-231 breast cancer cells. 
 
Figure 2  The mechanism of action of SKi and ABC294640 on growth arrest of 
androgen-independent LNCaP-AI cells.  SK1 selective inhibitors induce the ubiquitin-
proteasomal degradation of SK1.  SKi is a weak inhibitor of SK1 and SK2.  However, SKi 
and ABC294640 (SK2 selective inhibitor) also induce an activation of the proteasome that 
results in degradation of SK1 (possibly regulated via a dihydroceramide-dependent 
mechanism) and induce an increase in p53 and p21 expression.  Therefore, androgen-
independent LNCaP-AI prostate cancer cells undergo a p53/p21-induced growth arrest.   
 
Figure 3  Effect of the SK1 inhibitor, PF-543 on EAE disease progression.  C57BL/6 
mice were immunized subcutaneously on the back with 100 µg of MOG35-55 peptide (Sigma 
Genosys) in 50 µl of PBS emulsified with an equal volume of CFA (total 125 µg of 
Mycobacterium tuberculosis, strain H37RA, Difco, Detroit MI).  Each mouse also received 
intraperitoneally (i.p.) 100 ng/200 µl of PTX (Sigma, UK) in PBS on days 0 and 2 post 
immunization. EAE was scored according to a 0 - 5 scale as follows: 0, no clinical sign; 1, 
complete loss of tail tone; 2, hind limb weakness; 3, hind limb paralysis; 4, forelimb 
involvement; 5, moribund.  PF-543 (0.4mg/kg w/v) was administered i.p. daily from day 0 of 
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MOG immunization. The EAE control group received i.p. injection daily of the 20% 
cyclodextrin vehicle.  The figure shows clinical disease prgression in the EAE group versus 
EAE plus PF-543.  Also shown are images of SK1 expression and CD4+ cell, F4/80 
macrophage and CD11+ cell infiltration in the spinal cord  in the EAE plus PF-543 group 
versus EAE.  Also shown is the inhibition of SK1 activity by PF-543 using a radiometirc 
assay described by Lim et al., 2011b.  The results are shown as the % control SK1 activity 
(where control = 100% SK1 activity). 
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